We investigated the predictive value of the 3-month BCR-ABL1 transcript levels in terms of responses and outcome of 44 children and adolescents (<18 years at diagnosis) with chronic myeloid leukemia (CML) treated with high-dose imatinib (IM) (340 mg/m2/day). The transcript cutoff levels of 1% and 10% BCR-ABL1 IS were not predictive of either complete cytogenetic response at any time, overall molecular response (MR) and complete MR (CMR), and progression-free survival probabilities at 5 years. The 3-month transcript levels in children and adolescents with CML treated with high-dose IM do not appear to be informative for the prediction of outcomes.
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib / Giona, Fiorina; Saglio, Giuseppe; Santopietro, Michelina; Menna, Giuseppe; Putti, Maria Caterina; Micalizzi, Concetta; Iaria, Grazia; Santoro, Nicola; Ladogana, Saverio; Mura, Rosamaria; Burnelli, Roberta; Consarino, Caterina; Cosmi, Carlo; Moleti, Maria Luisa; Leszl, Anna; Tucci, Francesca; Nanni, Mauro; Diverio, Daniela; Biondi, Andrea; Locatelli, Franco; Foa, Roberto. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 180:6(2018), pp. 895-898. [10.1111/bjh.14458]
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib
GIONA, FiorinaPrimo
;Santopietro Michelina;Moleti, Maria Luisa;Locatelli, Franco;FOA, Roberto
2018
Abstract
We investigated the predictive value of the 3-month BCR-ABL1 transcript levels in terms of responses and outcome of 44 children and adolescents (<18 years at diagnosis) with chronic myeloid leukemia (CML) treated with high-dose imatinib (IM) (340 mg/m2/day). The transcript cutoff levels of 1% and 10% BCR-ABL1 IS were not predictive of either complete cytogenetic response at any time, overall molecular response (MR) and complete MR (CMR), and progression-free survival probabilities at 5 years. The 3-month transcript levels in children and adolescents with CML treated with high-dose IM do not appear to be informative for the prediction of outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giona_Early response_2018.pdf
accesso aperto
Tipologia:
Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
477.92 kB
Formato
Adobe PDF
|
477.92 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
